L. Fehrenbacher

发表

First-Line Herceptin® Monotherapy in Metastatic Breast Cancer

L. Harris, S. Shak, C. Vogel, 2001, Oncology.

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

N. Robert, D. Tripathy, S. Shak, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Lyndsay N Harris, L. Harris, S. Shak, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Greg Yothers, Peter A Kaufman, Norman Wolmark, 2005, The New England journal of medicine.

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

S. Shak, J. Baker, D. Watson, 2006, Breast Cancer Research.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, The New England journal of medicine.

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

N. Petrelli, N. Wolmark, R. Goldberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.

N. Petrelli, N. Wolmark, R. Goldberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

F. Kabbinavar, H. Hurwitz, L. Fehrenbacher, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

J. Berlin, A. Jimeno, D. Aisner, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer: Analysis of the NSABP B-31 Trial

S. Paik, J. Costantino, C. Geyer, 2017, JAMA oncology.

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial

James Dignam, Norman Wolmark, Mirsada Begovic, 1999, The Lancet.

Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).

Keunchil Park, J. Mazières, J. Vansteenkiste, 2015 .

Cost of care for patients in cancer clinical trials.

L. Fehrenbacher, B. Fireman, E. Gruskin, 2000, Journal of the National Cancer Institute.

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group.

Caroline Schenkel, L. Fehrenbacher, N. Roach, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer Jennifer C. LivaudaisDawn L. HershmanLaurel HabelLawrence Kushi • Scarlett Lin GomezChristopher I. LiAlfred I. NeugutLouis Fehrenbacher • Beti ThompsonGloria D. Coronado

A. Neugut, B. Thompson, L. Habel, 2012 .

14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)

J. Yi, J. Mazières, J. Vansteenkiste, 2015 .

Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004 .

A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer.

L. Hart, D. Ramies, L. Fehrenbacher, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

S. Reis, W. McCaskill-Stevens, S. Lippman, 2006 .

Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30

T. Julian, S. Swain, P. Ganz, 2018, Journal of the National Cancer Institute.

Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715)

L. Minasian, C. Moinpour, J. Unger, 2018, Journal of the National Cancer Institute.

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.

G. Hortobagyi, L. Minasian, C. Moinpour, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

K. Syrigos, D. Gandara, R. Dziadziuszko, 2017 .

Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative br

H. Gómez, N. Robert, C. Geyer, 2016 .

Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

T. Julian, J. Costantino, N. Wolmark, 2016, The Lancet.

Abstract S5-06: Randomized, placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG S1202)

C. Moinpour, J. Unger, L. Fehrenbacher, 2017 .

Routine preventive care and cancer surveillance in long-term survivors of colorectal cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol LTS-01.

D. Wickerham, C. Ko, P. Ganz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract S3-02: NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer

T. Julian, C. Geyer, D. Wickerham, 2015 .

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).

C. Loprinzi, A. Grothey, S. Dakhil, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxaliplatin–Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials

M. Tempero, A. Venook, L. Fehrenbacher, 2016, Pancreas.

Phase I I, R andomized T rial C omparing B evacizumab P lus Fluorouracil ( FU)/Leucovorin ( LV) W ith F U/LV A lone i n Patients W ith M etastatic C olorectal C ancer

F. Kabbinavar, H. Hurwitz, L. Fehrenbacher, 2003 .

Neurotoxicity (NT) in colon cancer (CC) survivors from NSABP Protocol C-07 comparing 5-FU + leucovorin (FULV) with the same regimen + oxaliplatin (FLOX): Preliminary results from NSABP Protocol LTS-01

D. Wickerham, C. Ko, P. Ganz, 2008 .

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

N. Petrelli, N. Wolmark, M. O’connell, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Organizational barriers to physician participation in cancer clinical trials.

Sarah M. Greene, Andrea Altschuler, Andrew Glass, 2005, The American journal of managed care.

Effect of medical oncologists' attitudes on accrual to clinical trials in a community setting.

T. Kolevska, L. Ackerson, C. Somkin, 2013, Journal of oncology practice.

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.

S. Paik, G. Tang, J. Costantino, 2015, The Lancet. Oncology.

Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.

L. Fehrenbacher, P. Lara, H. West, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.

L. Rubinstein, W. Barlow, M. Regan, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE.

M. Kris, R. Herbst, V. Miller, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

David M Jablons, Eric Holmgren, Roy S Herbst, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Xin Li, Roy S Herbst, Hai T Tran, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

W. Eiermann, H. Rugo, L. Fehrenbacher, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40

S. Paik, G. Tang, J. Costantino, 2015 .

NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer.

S. Paik, J. Costantino, C. Geyer, 2013 .

Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004 .

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study

E. Winer, P. Ellis, Chiun-Sheng Huang, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.

T. Julian, J. Costantino, N. Wolmark, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR)

Keunchil Park, J. Yi, J. Mazières, 2016, Pneumologie.

Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.

Dawn L Hershman, Lawrence H Kushi, Wei-Yann Tsai, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.

S. Paik, G. Tang, J. Costantino, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer.

J. Costantino, N. Wolmark, R. Livingston, 2009 .

Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme.

T. Kolevska, T. Cloughesy, S. Phuphanich, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.

C. Redfern, C. Higano, M. Carducci, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.

R. Laing, S. Chan, L. Fehrenbacher, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Lack of effect of bevacizumab on wound healing/bleeding complications when given 28–60 days following primary cancer surgery

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004 .

Lack of effect of bevacizumab on wound healing/bleeding complications when given 28-60 days following primary cancer surgery.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.

Keunchil Park, F. de Marinis, J. von Pawel, 2019, Lung cancer.

Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK)

P. Hegde, T. Mok, D. Gandara, 2017, Pneumologie.

Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.

E. Perez, J. Costantino, C. Geyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52

S. Paik, N. Wolmark, S. Swain, 2017 .

Gene expression and breast cancer mortality in Northern California Kaiser Permanente Patients: A large population-based case control study

S. Shak, J. Baker, D. Watson, 2005 .

Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy

W. Eiermann, H. Rugo, I. C. Tudor, 2019, JNCI cancer spectrum.

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

H. Rugo, I. C. Tudor, J. Chakrabarti, 2019, The oncologist.

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

Keunchil Park, D. Gandara, J. von Pawel, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study

T. Julian, C. Geyer, N. Wolmark, 2014, Breast Cancer Research and Treatment.

Chemotherapy for brain metastases in small-cell lung cancer.

D. Gandara, L. Fehrenbacher, D. Lau, 2008, Clinical lung cancer.

Multicenter, Phase II Trial of Exemestane as Third-Line Hormonal Therapy of Postmenopausal Women With Metastatic Breast Cancer

L. Fehrenbacher, A. Consonni, B. Cooper, 1999 .

Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

T. Julian, C. Geyer, P. Ward, 2021, Breast Cancer Research and Treatment.

Anti-mullerian hormone as a serum biomarker for risk of chemotherapy-induced amenorrhea.

P. Fasching, D. Schaid, C. Vachon, 2020, Journal of the National Cancer Institute.

Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer.

S. Reis, W. McCaskill-Stevens, L. Ford, 2015 .

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Norman Wolmark, Scott M Lippman, S. Reis, 2006, JAMA.

Abstract P3-12-01: Impact of treatment on quality of life (QOL) and menstrual history (MH) in the NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide

E. Perez, N. Wolmark, P. Ward, 2015 .

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

H. Rugo, I. C. Tudor, J. Chakrabarti, 2019, The oncologist.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

W. Eiermann, H. Rugo, I. C. Tudor, 2018, The New England journal of medicine.

Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).

W. Eiermann, H. Rugo, I. C. Tudor, 2018 .

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

J. Bryant, D. Wickerham, N. Wolmark, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

J. Vose, A. Zelenetz, M. Kaminski, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety of bevacizumab (Bv) therapy in combination with chemotherapy in subjects with non-small cell lung cancer (NSCLC) treated on ATLAS

J. Hainsworth, V. Miller, L. Fehrenbacher, 2008 .

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

J. Berlin, A. Jimeno, D. Aisner, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.

J. Hainsworth, L. Hart, L. Fehrenbacher, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer

Joseph P. Costantino, V. Craig Jordan, Victor G. Vogel, 2010, Cancer Prevention Research.

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

L. Saltz, C. Blanke, M. Moore, 2000, The New England journal of medicine.

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.

M. Rubin, J. Hainsworth, V. Miller, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.

S. Paik, J. Costantino, C. Geyer, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Keunchil Park, J. Yi, J. Mazières, 2016, The Lancet.

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

Jacob Silterra, David S. Shames, Craig A. Cummings, 2018, Nature Medicine.

Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.

N. Petrelli, N. Wolmark, M. O’connell, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.

S. Paik, J. Costantino, C. Geyer, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

Toyoaki Hida, Keunchil Park, D. Gandara, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission

B. Karlan, P. Sabbatini, L. Fehrenbacher, 2012, Clinical Cancer Research.

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.

Paul S Mischel, Albert Lai, Phioanh L Nghiemphu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

P Kelly Marcom, H. Rugo, B. Overmoyer, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement.

Laura A. Levit, H. Cohen, Laura A Levit, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.

R. Herbst, L. Hart, D. Ramies, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

E. Perez, J. Costantino, C. Geyer, 2010, The New England journal of medicine.

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.

S. Paik, G. Tang, J. Costantino, 2013, The Lancet. Oncology.

The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40

S. Paik, G. Tang, J. Costantino, 2017, Annals of Surgical Oncology.

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

J. Berlin, J. Hainsworth, F. Kabbinavar, 2005, Journal of surgical oncology.

Pivotal S tudy o f I odine I 1 31 T ositumomab f or Chemotherapy-Ref ractory L ow-Grade o r T ransformed Low-Grade B -Cell N on-Hodgkin's L ymphomas

J. Vose, A. Zelenetz, M. Kaminski, 2001 .

Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25.

D. Wickerham, N. Wolmark, S. Anderson, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease

M. Erlander, D. Sgroi, L. Habel, 2013, Breast Cancer Research.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

J. Berlin, A. Jimeno, D. Aisner, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Feasibility Study of a Weight Loss Intervention in Female Breast and Colorectal Cancer Survivors (SWOG S1008)

Sheri J. Hartman, J. Unger, J. Gralow, 2018, Obesity.

TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC).

R. Herbst, R. Hermann, L. Fehrenbacher, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the Ph III study OAK

D. Gandara, R. Dziadziuszko, J. Mazières, 2018, Pneumologie.

Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation

W. Eiermann, I. C. Tudor, Y. Im, 2018 .

The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.

G. Tang, J. Costantino, C. Geyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab added to neoadjuvant chemotherapy for breast cancer.

James A Young, Norman Wolmark, Rita S Mehta, 2012, The New England journal of medicine.

Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer

Dawn L. Hershman, Lawrence H. Kushi, Alfred I. Neugut, 2011, Breast Cancer Research and Treatment.

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

W. Scheithauer, H. Lenz, A. Zubel, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.

L. Harris, D. Tripathy, S. Shak, 2001, European journal of cancer.

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

J. Costantino, C. Geyer, D. Wickerham, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.

L. Habel, L. Fehrenbacher, C. Quesenberry, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1803 PEGGY: A phase II randomised study of the PI3-kinase (PI3K) inhibitor pictilisib (GDC-0941) plus paclitaxel in patients (pts) with hormone receptor (HR)-positive, HER2-negative locally recurrent or metastatic breast cancer (mBC)

R. Laing, L. Fehrenbacher, R. Roylance, 2015 .

Abstract 2837: A surrogate gene expression signature of tumor infiltrating lymphocytes (TILs) predicts degree of benefit from trastuzumab added to standard adjuvant chemotherapy in NSABP (NRG) trial B-31 for HER2+ breast cancer

J. Costantino, C. Geyer, D. Wickerham, 2015 .

Benign Papillary Breast Mass Lesions: Favorable Outcomes with Surgical Excision or Imaging Surveillance

J. Darbinian, L. Habel, L. Fehrenbacher, 2019, Annals of Surgical Oncology.

Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer

E. Perez, C. Geyer, P. Ward, 2022, Breast Cancer Research and Treatment.

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.

C. Moinpour, J. Unger, L. Fehrenbacher, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Jong-Hyeon Jeong, Hanna Bandos, Debora Fumagalli, 2013, Journal of the National Cancer Institute.

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.

E. Perez, J. Costantino, C. Geyer, 2012, The Lancet. Oncology.

Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

Greg Yothers, Michael Ewer, Norman Wolmark, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

H. Gómez, N. Robert, C. Geyer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

T. Julian, J. Costantino, N. Wolmark, 2016, The Lancet.

Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.

Keunchil Park, D. Gandara, J. von Pawel, 2019, European journal of cancer.

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer

C. Geyer, N. Wolmark, S. Swain, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer

A. Neugut, B. Thompson, L. Habel, 2011, Breast Cancer Research and Treatment.

Quality of life and symptoms in long-term survivors of colorectal cancer: results from NSABP protocol LTS-01

D. Wickerham, C. Ko, P. Ganz, 2017, Journal of Cancer Survivorship.

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.

S. Paik, C. Geyer, D. Wickerham, 2019, The Lancet. Oncology.

Reply to L. Cabel et al.

L. Habel, L. Fehrenbacher, A. Capra, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.

A. Buzdar, C. Geyer, N. Wolmark, 2010, Clinical breast cancer.

Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05.

J. Bryant, N. Wolmark, J. Grem, 1998, Journal of the National Cancer Institute.

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer.

S. Paik, J. Costantino, C. Geyer, 2019, Journal of the National Cancer Institute.

Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel

C. Higano, L. Fehrenbacher, J. Picus, 2007, Investigational New Drugs.

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41.

S. Paik, G. Tang, J. Costantino, 2016 .

Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).

G. Curigliano, A. Brenner, D. Cameron, 2021, European journal of cancer.

First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report.

L. Harris, S. Shak, M. Cobleigh, 2001, European journal of cancer.

Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR.

Keunchil Park, J. Yi, J. Mazières, 2016 .

Phase II trial of nab-paclitaxel as first-line therapy of hormone refractory metastatic prostate cancer (HRPC).

T. Kolevska, D. Goldstein, B. Fireman, 2009, Journal of Clinical Oncology.

MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice

R. Gomis, N. Wolmark, A. Wolff, 2021, JNCI cancer spectrum.

S2-3: NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis.

J. Costantino, N. Wolmark, S. Swain, 2011 .

Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group.

C. Vogel, L. Fehrenbacher, S. Jones, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

N. Robert, S. Shak, C. Vogel, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease

Xiao-Jun Ma, M. Erlander, D. Sgroi, 2013, Breast Cancer Research.

Randomized clinical trial eligibility rates for chemotherapy (CT) and antiangiogenic therapy (AAT) in a population-based cohort of newly diagnosed non-small cell lung cancer (NSCLC) patients.

L. Ackerson, C. Somkin, L. Fehrenbacher, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)

J. Hainsworth, V. Miller, F. Kabbinavar, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence

L. Habel, L. Fehrenbacher, Catherine Lee, 2020, Breast Cancer Research and Treatment.

OA 17.07 Long-Term Survival in Atezolizumab-Treated Patients with 2L+ NSCLC from Ph III Randomized OAK Study

D. Gandara, M. Satouchi, L. Fehrenbacher, 2017 .

Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study.

Keunchil Park, D. Gandara, L. Fehrenbacher, 2017 .

Use of raloxifene among women with a history of breast cancer

S. Sidney, B. Ettinger, L. Habel, 2006, Breast Cancer Research and Treatment.

O-0032PHASE III RANDOMIZED, PLACEBO(PL)-CONTROLLED, DOUBLE-BLIND STUDY OF INTRAVENOUS CALCIUM/MAGNESIUM (CAMG) TO PREVENT OXALIPLATIN-INDUCED SENSORY NEUROTOXICITY (SNT), N08CB: AN ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY STUDY1

C. Loprinzi, A. Grothey, S. Dakhil, 2013 .

Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An alliance for clinical trials in oncology study.

C. Loprinzi, A. Grothey, S. Dakhil, 2013 .

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab

C. Geyer, N. Wolmark, P. Ganz, 2021, NPJ breast cancer.

MA 10.03 3-Year Survival and Duration of Response in Randomized Phase II Study of Atezolizumab vs Docetaxel in 2L/3L NSCLC (POPLAR)

J. Mazières, J. Vansteenkiste, L. Fehrenbacher, 2017 .

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.

S. Paik, G. Tang, J. Costantino, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

136PD_PR 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR)

J. Mazières, J. Vansteenkiste, L. Fehrenbacher, 2018 .

Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas

J. Vose, A. Zelenetz, M. Kaminski, 2010 .

A multi-institution phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer

D. Gandara, L. Fehrenbacher, A. Davies, 2005 .

Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.

B. Fireman, L. Fehrenbacher, K. Ikeda, 1991, Journal of neurology, neurosurgery, and psychiatry.

Safety of First-Line Letrozole Compared with Lapatinib Plus Letrozole in Patients with Postmenopausal Hormone Receptor Positive Metastatic Breast Cancer: EGF30008 Study.

A. Makris, X. Pivot, L. Fehrenbacher, 2009 .

275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM)

K. Gelmon, G. Curigliano, D. Cameron, 2020 .

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, The New England journal of medicine.

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

L. Harris, S. Shak, C. Vogel, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

F. Kabbinavar, L. Fehrenbacher, D. Jablons, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, The New England journal of medicine.

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

N. Petrelli, N. Wolmark, R. Goldberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.

A. Buzdar, C. Geyer, N. Wolmark, 2010, Clinical breast cancer.

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

R. Herbst, J. Nemunaitis, F. Kabbinavar, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study.

W. McCaskill-Stevens, J. Costantino, D. Wickerham, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/ NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer

S. Paik, J. Costantino, C. Geyer, 2019 .

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

E. Perez, J. Costantino, C. Geyer, 2010, The New England journal of medicine.

Benign Papillary Breast Mass Lesions: Favorable Outcomes with Surgical Excision or Imaging Surveillance

J. Darbinian, L. Habel, L. Fehrenbacher, 2019, Annals of Surgical Oncology.

Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

T. Julian, J. Costantino, N. Wolmark, 2016, The Lancet.

Abstract OT1-03-15: The METRIC trial: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC)

R. Nanda, L. Fehrenbacher, A. Forero, 2016 .

SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa).

A. Wozniak, D. Gandara, J. Moon, 2012 .

NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).

M. Buyse, T. Julian, S. Paik, 2012 .